Journal of Clinical and Experimental Ophthalmology
Open Access

James T Rosenbaum

Publications

• Case Report
  Methotrexate as a Corticosteroid-Sparing Agent for Thyroid Eye Disease
  Author(s): Erick Rivera-Grana, Phoebe Lin, Eric B. Suhler and James T Rosenbaum Erick Rivera-Grana, Phoebe Lin, Eric B. Suhler and James T Rosenbaum
  
  Objective: Thyroid eye disease (TED) is generally treated with oral corticosteroid therapy. A steroid sparing drug could be a useful adjunct. We reviewed our experience with methotrexate as a corticosteroid sparing agent to treat TED. Methods: Retrospective chart review from two eye inflammation clinics. Patients with TED who were unable to discontinue prednisone therapy without disease recurrence were included. Results: 14 patients who were receiving an average of 32 mg/day of prednisone were treated with methotrexate, usually 15 mg/week orally or 20 mg/week subcutaneously. Five patients discontinued therapy for a lack of benefit or intolerance. Of the 9 patients who remained on methotrexate, all were able to discontinue prednisone completely after an average duration of 7.5 months. Improved visual acuity by at least tw.. View More»
  DOI: 10.4172/2155-9570.1000422

  Abstract PDF

Relevant Topics